Breath-actuated inhaler

A new disposal breath-actuated inhaler was recently unveiled by Bang & Olufsen Medicom designed for use with liquid drug formulations suitable for pMDIs (pressurised metered dose inhalers). Manufacturers claim the inhaler, named Aspira, offers a “cost-effective and improved pulmonary drug delivery for treating diseases, including diabetes.”

Advances in inhalers have made the daily management of diseases easier for patients. For example, breath-actuated inhalers – which are automatically activated when the user inhales from the mouthpiece. This automatic release of the medication removes a large stumbling block for patients who have trouble co-ordinating their movements with conventional press-and-breath inhalers and is therefore especially suitable for children and the elderly. In addition, Aspira holds a unique patent which reduces the particle flow rate thus ensuring improved drug delivery to the lungs.

Another key feature for the device is an integrated dose-counter, which can record up to 200 individual doses. This feature is important for people who have difficulties tracking their medication and can help with patient compliance issues. The dose counter will only register fired doses and will therefore reliably inform the patient of doses taken and remaining in the canister.

Latest Issues

AfPP Plymouth Regional Conference

TBC, Plymouth
10th May 2025

Theatres and Decontamination Conference

CBS Arena
20th May 2025

BAUN Day Educational Event

Hilton, Belfast
6th June 2025

EBME Expo 2025

Coventry Building Society Arena, UK
25th - 26th June 2025